Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

ETFis BioShares Biotechnology Products Fund buy tamam

Startpreis
32,86 ?
24.05.17 / 50%
Kursziel
45,55 €
22.06.18
Rendite (%)
12,24 %
Endpreis
36,88 €
22.06.18
Zusammenfassung
Diese Einschätzung wurde am 22.06.18 mit einem Endkurs von 36,88 € beendet. Aufwärts ging es für die BUY Einschätzung von tamam mit einer Rendite von 12,24 %. tamam hat 50% Zuversicht bei dieser Einschätzung
Rendite ohne Dividenden (%)
Name 1W 1M 1J 3J
ETFis BioShares Biotechnology Products Fund - - - -
iShares Core DAX® 0,48 % -0,04 % 13,34 % 17,33 %
iShares Nasdaq 100 1,29 % 0,50 % 40,10 % 50,53 %
iShares Nikkei 225® 1,30 % -2,13 % 19,86 % 4,94 %
iShares S&P 500 0,83 % 0,19 % 29,76 % 43,43 %

Kommentare von tamam zu dieser Einschätzung

In der Diskussion ETFis BioShares Biotechnology Products Fund diskutieren
Einschätzung Buy
Rendite (%) 12,24 %
Kursziel 45,55
Veränderung
Endet am 22.06.18

BioShares Biotechnology Products Fund (BBP) which invests in companies

that have at least one primary product that's received FDA approval, is up roughly 42% since its inception at the end of 2014 compared to a loss of 4% for IBB during the same time frame.


BBP has a portfolio that has performed almost as well as can be expected, especially in 2017. Take a look at this chart with the year-to-date performance of the fund's biggest components.
Among the top 10 holdings, all have posted double-digit gains with seven components delivering 25%+ gains.



The other advantage the fund has is that a number of its holdings are in the sweet spot of being developed enough to generate meaningful revenue from their approved product line yet being small enough that they can be potential takeover targets.

Current holdings such as Exelixis (NASDAQ: Exel)and Acadia (NASDAQ: ACAD) have been rumored as potential takeover targets for a while so further action could be in store for the fund in the near future as well.

Equal weighting the mature biotech players has been a strategy that's paid off for investors in the last year. The relatively limited exposure to the likes of Celgene and Gilead, which are still nearly 50% off of

recent highs, has made the fund more attractive than its more well-known counterpart. This fund will underperform when the mega-cap biotech names begin to rally again, but over the long-term this ETF should hold up well to IBB given its more diversified portfolio.












Einschätzung Buy
Rendite (%) 12,24 %
Kursziel 45,55
Veränderung
Endet am 22.06.18

(Vom Mitglied beendet)

Beendete Einschätzungen von tamam zu ETFis BioShares Biotechnology Products Fund

buy
ETFis BioShares Biotechnology Products Fund

Startkurs
Kursziel
Rendite (%)
36,88 ?
22.06.18
45,55 €
22.06.18
0,00 %
22.06.18